Application 091084
- Type
- ANDA
- Sponsor
- WATSON LABS FLORIDA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | TELMISARTAN; HYDROCHLOROTHIAZIDE | TELMISARTAN; HYDROCHLOROTHIAZIDE | TABLET; ORAL | 40MG; 12.5MG | No | No |
| 002 | TELMISARTAN; HYDROCHLOROTHIAZIDE | TELMISARTAN; HYDROCHLOROTHIAZIDE | TABLET; ORAL | 80MG; 12.5MG | No | No |
| 003 | TELMISARTAN; HYDROCHLOROTHIAZIDE | TELMISARTAN; HYDROCHLOROTHIAZIDE | TABLET; ORAL | 80MG; 25MG | No | No |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.